How long does CJC-1295 DAC stay in your system?
CJC-1295 DAC has a published half-life of 5.8 to 8.1 days. By the standard pharmacology rule of thumb, a drug is about 97% eliminated after roughly five half-lives, which here works out to between 29 and 40.5 days (4.1 to 5.8 weeks). This applies only to CJC-1295 with DAC; the non-DAC form has no published human half-life.
Source: Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683) · Peer-reviewed · measured: subcutaneous · dataset reviewed September 23, 2026
What is the half-life of CJC-1295 DAC?
CJC-1295 with DAC has a published half-life of 5.8 to 8.1 days after subcutaneous injection, from a 2006 study in the Journal of Clinical Endocrinology and Metabolism in healthy adults aged 21 to 61. CJC-1295 is a modified analogue of the active GHRH(1-29) fragment, and the DAC, a drug affinity complex, is a chemical group that lets it bond to albumin after injection.
That bond is the whole story. Unmodified GHRH(1-29), measured as sermorelin, disappears with a half-time of 4.3 ± 1.4 minutes. Bound to albumin, CJC-1295 is shielded from enzymes and from filtration by the kidney, and it persists for days. The DAC produces this half-life, and it is the reason the DAC and non-DAC forms cannot share a number.
How much CJC-1295 DAC is left after each half-life?
Each half-life removes half of whatever is left, so the percentages are pure arithmetic and the same for any compound; only the clock changes. For CJC-1295 DAC, one half-life is 5.8 to 8.1 days. The rows below run that forward for a single amount with nothing added.
| Half-lives elapsed | Time elapsed | Remaining | Cleared |
|---|---|---|---|
| 1 | 5.8 to 8.1 days | 50% | 50% |
| 2 | 11.6 to 16.2 days | 25% | 75% |
| 3 | 17.4 to 24.3 days (2.5 to 3.5 weeks) | 12.5% | 87.5% |
| 4 | 23.2 to 32.4 days (3.3 to 4.6 weeks) | 6.25% | 93.75% |
| 5 | 29 to 40.5 days (4.1 to 5.8 weeks) | 3.13% | 96.88% |
| 6 | 34.8 to 48.6 days (5 to 6.9 weeks) | 1.56% | 98.44% |
| 7 | 40.6 to 56.7 days (5.8 to 8.1 weeks) | 0.78% | 99.22% |
Why do the numbers differ between sources?
The most important difference is not between sources but between products. The 5.8 to 8.1 day figure belongs to CJC-1295 with DAC only. Material sold as CJC-1295 without DAC, also called Mod-GRF (1-29), has no controlled human pharmacokinetic study at all, and borrowing the DAC figure for it is a category error.
Within the DAC data, the range reflects variation among the healthy adults studied. Development of CJC-1295 was discontinued before it reached a label, so this single study remains the reference.
What does a half-life not tell you?
It does not describe growth hormone or IGF-1. CJC-1295 with DAC raises growth hormone by acting on the pituitary GHRH receptor, and the IGF-1 that follows has its own kinetics. A days-long half-life means exposure to the stimulus is prolonged, but how the axis responds over that time is a separate question.
It also says nothing about safety under sustained exposure, because no clinical outcome trials were completed before development stopped. CJC-1295 is prohibited in sport by WADA, and whether it is detected depends on the assay, not on this half-life.
Can you run the numbers yourself?
The estimator applies the same decay arithmetic to any half-life, starting amount and time you enter. It opens with CJC-1295 DAC's published value loaded. Type another figure to see how sensitive the result is to it.
Published value: 5.8 to 8.1 days (Subcutaneous) · Teichman et al., J Clin Endocrinol Metab 2006 (PMID 16352683) · Compound profile
Show the math
What are the limits of this estimate?
Everything above is a single-compartment approximation: one pool of drug, falling by the same fraction in every interval. Real elimination varies with kidney and liver function, body composition, formulation and route, and a published figure describes only the route and the people it was measured in. Many compounds also show a fast distribution phase before the slower elimination the table describes.
A half-life is not a dosing schedule. Labelled intervals come from clinical trials that measured outcomes and tolerability, and nothing on this page suggests when to take, repeat or stop anything. Whether CJC-1295 DAC is out of your system for drug-testing purposes is a different question again. Tests often look for metabolites rather than the parent compound, and the answer depends on the assay, its sensitivity and the sample type, none of which a plasma half-life captures.
FAQ.
Does CJC-1295 without DAC have the same half-life?
No. The published 5.8 to 8.1 day figure belongs to CJC-1295 with DAC only. The DAC binds albumin and produces that half-life, and no controlled human study of the non-DAC form exists, so there is no figure to give for it.
Why does CJC-1295 with DAC last days when sermorelin lasts minutes?
Both act on the GHRH receptor, but CJC-1295 with DAC carries a drug affinity complex that bonds to albumin in the blood, protecting it from breakdown and renal filtration. Unmodified GHRH(1-29), measured as sermorelin, has a disappearance half-time of 4.3 ± 1.4 minutes.
Who was the CJC-1295 DAC half-life measured in?
Healthy adults aged 21 to 61, after subcutaneous injection, in a study published in 2006. CJC-1295 never reached approval, so no label exists, and the figure may not describe other populations.
For what the evidence on CJC-1295 DAC actually shows, read the CJC-1295 DAC profile. For approval and regulatory position, see is CJC-1295 DAC legal. The half-life reference lists every sourced value side by side, including the compounds where a number circulates online with no reliable human data behind it.